Nicotinamide riboside (NR)

The interesting gap is between engaging NAD metabolism and improving cognition, blood pressure or other outcomes. The human studies let us examine those questions separately.

A change in a laboratory marker, a test score and everyday function are different outcomes. A statistically detectable result does not by itself tell us whether someone would notice a worthwhile difference.

Check the measured endpoint, comparison and study population. The full profile preserves effect estimates and the source's clinical-significance assessment, including when that assessment is not supplied.

The claim to test: Raising NAD means better cognition or slower aging.

What the reviewed records say:

The gap: NAD-related measures are biological signals. They do not establish cognitive benefit, healthspan or lifespan.

Durability, effects in other populations and healthy-lifespan outcomes need their own evidence.

Independent replication, meaningful human outcomes, longer follow-up and better safety reporting would make these results easier to interpret.

NAD-related measures are biological signals. They do not establish cognitive benefit, healthspan or lifespan.